Peter Feinstein
GENERAL PARTNER
Peter co-founded BioVentures Investors with Marc Goldberg in 1999. He has advocated for, participated in and championed the biotechnology industry for over 26 years. Peter has advised a broad range of life science companies on public offerings, mergers, limited partnerships, private placements, and start-ups. He pioneered the approach of establishing valuation based on scientific and business achievements prior to product sales.
Founded Feinstein Kean HealthCare
Peter
founded the leading biotechnology communications firm, Feinstein Kean
Healthcare, in Cambridge in 1987. The firm was sold to the WPP group in
1999, after building a stellar reputation and a unique blend of
services to support the development of biotech companies and the
marketing of biopharmceutical products. Clients included Genzyme,
Biogen, Vertex Pharmaceuticals, Amgen, Abiomed, Novartis, Sepracor and
others.
Co-Founded Mass Biotech Council
In 1985,
Peter co-founded the Massachusetts Biotechnology Council. He served as
its executive director during its initial years and as a board member
from 1985 through 1997. In 1990, he received recognition for his work
for the industry as a Finalist in the Entrepreneur of the Year
competition.
Biogen
In 1981, Peter was hired by
Dr. Walter Gilbert to direct Biogen’s investor relations and
communications activities in Europe and the United States.
Peter is a member of the Executive Committee of the Board of Advisors of the Harvard-MIT Health Science and Technology Division and serves as Chair of its Development Committee. He also co-chaired the Leadership Circle at the Whitehead Institute for Biomedical Research, and is a member of its Board of Associates.
Prior to becoming active in the biotechnology industry, Peter was a financial journalist and documentary filmmaker. He received his B.A. degree in English Literature from New York University in 1969.
...
Peter is currently a member of the Board of Directors of Cylene Pharmaceuticals, BioValve Technologies, Hydrocision, Rcadia Medical Imaging, and Sciona, Inc., where he served as CEO during a six-month interim period. He has also been a board member at HospitalCare Online, nTouch Research Corp., New Chemical Entities, and sGC Pharmaceuticals.
Peter Feinstein GENERAL PARTNER